Search research articles
Contact Us
Filters
Showing results (151-160 of 169) with videos related to
Page
of 17
Sort By:
Scientific Reports
|
August 30, 2024
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
Margherita Rimini, Margarida Montes, Elisabeth Amadeo, et al.
Liver Cancer
|
April 22, 2026
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma
Edoardo G Giannini, Andrea Pasta, Giulia Pieri, et al.
Journal of Clinical Medicine
|
July 13, 2024
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study
Paolo Gallo, Antonio De Vincentis, Francesca Terracciani, et al.
Hepatology (Baltimore, Md.)
|
July 27, 2018
Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study
Alessandro Vitale, Fabio Farinati, Giulia Noaro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE Score
Lorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
The American Journal of Gastroenterology
|
June 2, 2021
Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience
Luca Rinaldi, Vincenzo Messina, Vito Di Marco, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
Antonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
Inflammatory Bowel Diseases
|
May 17, 2022
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Expert Opinion on Pharmacotherapy
|
June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
Antonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Expert Opinion on Biological Therapy
|
December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 169) with videos related to
Sort By:
Page
of 17
Scientific Reports
|
August 30, 2024
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
Margherita Rimini, Margarida Montes, Elisabeth Amadeo, et al.
Liver Cancer
|
April 22, 2026
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma
Edoardo G Giannini, Andrea Pasta, Giulia Pieri, et al.
Journal of Clinical Medicine
|
July 13, 2024
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study
Paolo Gallo, Antonio De Vincentis, Francesca Terracciani, et al.
Hepatology (Baltimore, Md.)
|
July 27, 2018
Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study
Alessandro Vitale, Fabio Farinati, Giulia Noaro, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE Score
Lorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
The American Journal of Gastroenterology
|
June 2, 2021
Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience
Luca Rinaldi, Vincenzo Messina, Vito Di Marco, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
Antonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
Inflammatory Bowel Diseases
|
May 17, 2022
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Expert Opinion on Pharmacotherapy
|
June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
Antonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Expert Opinion on Biological Therapy
|
December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Page
of 17